This document provides prior authorization requirements and clinical prerequisites for a broad set of specialty pharmacy products used across oncology, rheumatology, dermatology, gastroenterology, pulmonary, and neurologic indications. Coverage is tied to FDA‑approved indications and typically requires documentation of indication‑specific diagnostics or biomarkers (for example, HCV RNA within the prior 6 months for HCV direct‑acting antivirals, right‑heart catheterization hemodynamics for pulmonary arterial hypertension, and complement testing to confirm hereditary angioedema).
Common administrative expectations include specialist prescribing or consultation when specified, evidence of prior trials or contraindications to preferred or conventional therapies (step‑therapy), and demonstration of clinical benefit at renewal. Typical initial authorization periods are 6 months for many biologics and select agents, with renewals commonly set to 12 months, unless a drug‑specific duration is noted (for example, TYMLOS initial coverage is limited to 24 months).
The policy emphasizes concurrent‑therapy exclusions and safety‑related contraindications that affect coverage decisions (examples: no concurrent use of multiple systemic biologics or targeted small molecules for the same indication; for PAH agents, no concurrent nitrates/PDE inhibitors and hemodynamic confirmation by right‑heart catheterization with mean PAP > 20 mmHg, PCWP ≤ 15 mmHg, and PVR > 2 Wood units).
Providers should submit prior authorization requests with the required objective documentation (laboratory results, imaging, specialist consultation notes, and prior‑therapy trial documentation) as specified for each product to avoid delays or denials.